GLP-1 Receptor Agonists for Pharmacologically Induced Weight Gain
This Viewpoint discusses the use of glucagon-like peptide-1 (GLP-1) receptor agonists as a strategy to manage psychotropic-induced weight gain.
Prediction: Novo Nordisk Will Soar by 2026
Novo Nordisk (NYSE: NVO) has dropped over 50%, but its expanding GLP-1 pipeline and bold $5.2 billion acquisition could drive the next phase of explosive growth. With analysts turning bullish, investors might be looking at one of 2025’s biggest comeback stories. Stock prices used were the market prices of Oct. 28, 2025. The video was […]
Novo Nordisk’s Obesity Pill Shows Cardiovascular Benefits, Comparable Efficacy to Injection
Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar control and reduced cardiovascular risk factors,… Reuters Health Information
From falling knife to opportunity: my take on Diageo shares
The Diageo (LSE: DGE) share price has fallen more than 55% since early 2022, while the FTSE 100 has climbed around 35% over the same period. For a long time, I saw the stock as a classic falling knife and stayed well away. But markets often overshoot in both directions. Taking a contrarian stance is […]
Hims & Hers: GLP-1 Partnership Could Unlock Value
M4 drug discovery: human drug predictions from integrated pre-clinical insights exemplified with a GLP1-R agonist
Drug discovery utilises cell- and animal-systems to predict human responses. These different systems provide different drug discovery insights. However, there is currently no methodology to integrate all these insights into single quantitative framework. This study presents a new methodology — M4 drug discovery — which achieves such an integration. The method integrates: a) Multi-timescale data […]
De-escalating GLP-1s to Every-2-Weeks Maintenance Option
In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and metabolic improvements with every-other-week dosing. Medscape Medical News
Ozempic maker Novo Nordisk cuts sales and profit forecasts again
Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug market The maker of the weight-loss drugs Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments. Novo Nordisk’s chief executive, Mike Doustdar, […]
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)
Abstract Aims Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of […]
One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
Abstract Aims Real-world studies of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage. We describe patterns across individual subclasses, and in overall class-level models, we examined clinical characteristics associated with […]